[A26-66] Deucravacitinib (psoriatic arthritis) – Benefit assessment according to §35a Social Code Book V
Last updated 01.09.2026
Project no.:
A26-66
Commission:
Commission awarded on 01.06.2026 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Skin and hair
Indication:
Adults with active psoriatic arthritis
Result of dossier assessment:
- Patients who have had an inadequate response or who have been intolerant to a prior disease-modifying antirheumatic drug (DMARD) therapy: added benefit not proven
- Patients who have had an inadequate response or who have been intolerant to a prior therapy with biologic DMARDs: added benefit not proven
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
DOI:
https://doi.org/10.60584/A26-66
| Project no. | Title | Status |
|---|---|---|
| A23-34 | Deucravacitinib (plaque psoriasis) – Benefit assessment according to §35a Social Code Book V | Commission completed |